Étiquette : psychose

Bridging the Gap ? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States, Mihai Avram et al., 2021

Bridging the Gap ? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States Mihai Avram, Helena Rogg, Alexandra Korda, Christina Andreou, Felix Müller and Stefan Borgwardt Frontiers in Psychiatry, 2021, Volume 12, Article 706017, 1-13. Doi : 10.3389/fpsyt.2021.706017   Psychiatry has a well-established tradition of comparing drug-induced experiences to psychotic symptoms, based on shared phenomena such as altered perceptions. The present review focuses on experiences induced by classic psychedelics, which are substances capable of eliciting powerful psychoactive effects, characterized by distortions/alterations of several neurocognitive processes (e.g., hallucinations). Herein we refer to such experiences as psychedelic states. Psychosis is a clinical syndrome defined by impaired reality testing, [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin and glutamate systems, William E. Fantegrossi et al., 2018

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin and glutamate systems William E. Fantegrossi, Cathryn D. Wilson, and Michael D. Berquist III Drug Metabolism Reviews, 2018, 50, (1), 65–73. doi : 10.1080/03602532.2018.1428343 Abstract An association between marijuana use and schizophrenia has been noted for decades, and the recent emergence of high-efficacy synthetic cannabinoids (SCBs) as drugs of abuse has lead to a growing number of clinical reports of persistent psychotic effects in users of these substances. The mechanisms underlying SCB-elicited pro-psychotic effects is unknown, but given the ubiquitous neuromodulatory functions of the endocannabinoid system, it seems likely that agonist actions at cannabinoid type-1 [...]

Lire la suite

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients, Diana M. Martinez, MD Medscape .com, 2020

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]

Lire la suite

PTSD as a mediator of the relationship between trauma and psychotic experiences, Daniela Strelchuk et al, 2020

PTSD as a mediator of the relationship between trauma and psychotic experiences Daniela Strelchuk, Gemma Hammerton, Nicola Wiles, Jazz Croft, Katrina Turner, Jonathan Heron and Stanley Zammit Psychological Medicine, 2020, 1–9. doi : 10.1017/S0033291720004821   Abstract Background : Traumatic experiences are associated with a higher risk of psychotic illnesses, but little is known about potentially modifiable mechanisms underlying this relationship. This study aims to examine whether post-traumatic stress disorder (PTSD) symptoms mediate the relationship between trauma and psychotic experiences (PEs). Methods : We used data from the Avon Longitudinal Study of Parents and Children to examine whether: PTSD symptoms mediate the relationships between (a) childhood trauma and [...]

Lire la suite

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale, Dr Christian SUEUR, GRECC, septembre 2020.

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale   Dr Christian SUEUR, GRECC, septembre 2020.     Psychédéliques : neurobiologie et psychopharmacologie : 1 - 3 Psychédéliques et réactions indésirables : 4 - 5 Psychédéliques et psychopathologie : 6 - 7 Psychédéliques et « psychoses induites » : 8 - 9 Psychédéliques et “Flash Backs” (Hallucinogen-Persisting Perception Disorders) : 10 - 11 Psychédéliques et « Bad trip » : 11 Psychédéliques et Réduction des risques : 12  

Lire la suite

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies, Sagnik Bhattacharyya et al., 2012,

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054   Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]

Lire la suite

Bibliographie : Mescaline et Peyotl, Dr Christian SUEUR, GRECC, avril 2020.

Bibliographie : Mescaline et Peyotl   Dr Christian SUEUR, GRECC, avril 2020.   1 - Mescaline et Peyotl, Histoire et culture : 1 - 2 2 - Neuro-Psychophysiologie de la mescaline : 3 - 4 3 - Pharmacologie de la mescaline : 5 - 7 4 - Toxicologie de la mescaline : 8 5 - Complications psychiatriques de la mescaline : 8 6 - Ethnopharmacologie du Peyotl : 9 - 11 7 - Mescaline et thérapie psychédélique : 12 - 13    

Lire la suite